Abstract

Simple SummaryThe worldwide prevalence of diabetes mellitus (DM) in 2020 has been estimated at 463 million patients. About 90% of patients with diabetes have type 2 diabetes mellitus (T2D), caused primarily by insulin resistance and insufficiency. However, the specific etiology of T2D remains unknown. Sodium glucose cotransporter 2 (SGLT2) inhibitors are a novel class of anti-diabetic drugs that act independently of insulin and reduce blood glucose concentrations by inhibiting the reabsorption of glucose at renal proximal tubules. SGLT2 inhibitors have highlighted the role of the kidneys in glycemic control in diabetes. The kidneys have multiple roles in systemic glucose metabolism, such as glucose reabsorption, gluconeogenesis, and insulin degradation. Therefore, putative renal hyperfunction might contribute to the development of T2D. The present study characterized rats from a strain of novel type 2 diabetes model with enlarged kidneys (DEK). Their kidneys have increased parenchyma (nephrons and tubules), and uninephrectomy immediately after the onset inhibited the development of T2D for a significant period in DEK rats. These results highlight the contribution of kidney to the development of T2D, and indicate that the kidneys are therapeutic targets to prevent T2D.The kidneys participate in the regulation of systemic glucose metabolism via gluconeogenesis, insulin degradation, and the tubular reabsorption of glucose. The present study characterized rats from a strain of a novel type 2 diabetes model with enlarged kidneys (DEK). Histological and biochemical analyses of DEK rats were performed to assess the relationships between their kidneys and hyperglycemia. The kidney weight of diabetic DEK (DEK-DM) gradually increased over time from the onset of diabetes, with the glomerular number being higher in DEK-DM than in normal DEK (DEK-cont). A positive correlation between blood glucose level and kidney weight was observed in DEK-DM. The similar glomerular size and single glomerular creatinine clearance in DEK-cont and DEK-DM indicated that glomerular hypertrophy and hyperfiltration were not involved in the renal enlargement. Uninephrectomy (1/2Nx) in DEK-DM resulted in a reduction in blood glucose level at 7–28 post-operation days, with this concentration remaining lower than in Sham group until 84 days post-operation. 1/2Nx also improved systemic conditions, including reduced body weight gain, polyuria, polydipsia, and hyperphagia. Plasma concentrations of Na, total cholesterol, albumin, and total protein were higher, and urinary excretion of glucose, urea nitrogen, and proteins were lower, in the 1/2Nx than in the Sham group. Remnant kidney weight was two-fold higher in the 1/2Nx than in the Sham group 84 days later. In addition, 1/2Nx resulted in renal tubular dilatation but not in the progression of fibrosis or glomerular lesions. Taken together, these findings indicate that enlarged kidneys were associated with the onset of diabetes and with the resistance to diabetic nephropathy in DEK-DM.

Highlights

  • The worldwide prevalence of diabetes mellitus (DM) in 2020 has been estimated at 463 million patients

  • To characterize the differences between their kidneys, diabetes model with enlarged kidneys (DEK)-cont and DEKDM rats were sacrificed at age 30 weeks, and their kidneys were weighed, the numbers of Glomerular Number (GN) counted, and glomerular size measured

  • Diabetes is generally accompanied by glomerular hypertrophy, glomerular size was similar in DEK-DM and DEK-cont rats (10,971.8 ± 236.0 vs. 11,870.6 ± 358.5 μm2, p > 0.05) (Figure 1c), suggesting that enlarged kidneys of DEK-DM rats are not accompanied by glomerular hypertrophy

Read more

Summary

Introduction

The worldwide prevalence of diabetes mellitus (DM) in 2020 has been estimated at 463 million patients. Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are a novel class of anti-diabetic drugs with a different mechanism of action, reducing blood glucose concentrations by inhibiting glucose reabsorption in renal tubules [3,4]. The kidneys release lower amounts of endogenous glucose into the circulation than the liver This relationship, is reversed after ingestion of food, due to the suppression of gluconeogenesis and the promotion of glycogenesis in the liver [8,10,11]. The amount of glucose released from the liver was found to be only ~30% higher in patients with DM than in non-diabetic individuals, whereas glucose release from the kidneys was three-fold in patients with DM [12]. The present study investigated whether the kidneys could accelerate diabetes in DEK rats

Animals
Measurement of Glomerular Size
Nephrectomy
Immunofluorescence and Pathological Analysis of Kidney
Biochemical Analysis
Characterization of Enlarged Kidneys in DEK-DM Rats
Effect of Uninephrectomy on Biochemical Parameters
Histology of Nephrectomized Kidneys
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call